Investors Sue Unicycive Therapeutics Over Securities Fraud Allegations
Shareholders who lost money in Unicycive Therapeutics have the opportunity to lead a securities fraud class action lawsuit. The complaint alleges false and misleading statements regarding manufacturing and regulatory compliance.
The Law Offices of Howard G. Smith has announced an opportunity for investors who have suffered substantial losses in Unicycive Therapeutics, Inc. (UNCY) to lead a securities fraud class action lawsuit. The suit alleges that Unicycive Therapeutics made materially false and misleading statements and failed to disclose adverse information about its business operations and prospects.
The complaint specifically claims that Unicycive Therapeutics did not inspect its third-party manufacturing vendor's facility or audit its compliance with current good manufacturing practices (cGMP). Consequently, the company allegedly lacked a reasonable basis to believe the vendor had resolved deficiencies cited by the U.S. Food and Drug Administration (FDA).
Furthermore, the lawsuit asserts that there was an undisclosed risk that the FDA would require additional information regarding the vendor's manufacturing practices. This situation is alleged to have created a delay in the regulatory approval of OLC, making the company's prior positive statements misleading and without a reasonable basis.
Investors who incurred losses in Unicycive Therapeutics are encouraged to contact The Law Offices of Howard G. Smith before November 2, 2026. The firm is seeking investors to serve as lead plaintiffs in the action. No action is required at this time to remain a member of the class.